Author: ["Shivalingappa Venkatesha","Mourad Toporsian","Chun Lam","Jun-ichi Hanai","Tadanori Mammoto","Yeon M Kim","Yuval Bdolah","Kee-Hak Lim","Hai-Tao Yuan","Towia A Libermann","Isaac E Stillman","Drucilla Roberts","Patricia A D'Amore","Franklin H Epstein","Frank W Sellke","Roberto Romero","Vikas P Sukhatme","Michelle Letarte","S Ananth Karumanchi"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Preeclampsia is a pregnancy-specific hypertensive syndrome that causes substantial maternal and fetal morbidity and mortality. Maternal endothelial dysfunction mediated by excess placenta-derived soluble VEGF receptor 1 (sVEGFR1 or sFlt1) is emerging as a prominent component in disease pathogenesis. We report a novel placenta-derived soluble TGF-β coreceptor, endoglin (sEng), which is elevated in the sera of preeclamptic individuals, correlates with disease severity and falls after delivery. sEng inhibits formation of capillary tubes in vitro and induces vascular permeability and hypertension in vivo. Its effects in pregnant rats are amplified by coadministration of sFlt1, leading to severe preeclampsia including the HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome and restriction of fetal growth. sEng impairs binding of TGF-β1 to its receptors and downstream signaling including effects on activation of eNOS and vasodilation, suggesting that sEng leads to dysregulated TGF-β signaling in the vasculature. Our results suggest that sEng may act in concert with sFlt1 to induce severe preeclampsia.Cite this article
Venkatesha, S., Toporsian, M., Lam, C. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12, 642–649 (2006). https://doi.org/10.1038/nm1429 